Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Kallikrein 5 Antibodies:
anti-Mouse (Murine) Kallikrein 5 Antibodies:
anti-Human Kallikrein 5 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Kallikrein 5 Primary Antibody for EIA, WB - ABIN358888
Planque, de Monte, Guyetant, Rollin, Desmazes, Panel, Lemarié, Courty: KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. in Biochemical and biophysical research communications 2005
Show all 5 references for ABIN358888
Human Polyclonal Kallikrein 5 Primary Antibody for WB - ABIN390305
Michael, Sotiropoulou, Pampalakis, Magklara, Ghosh, Wasney, Diamandis: Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. in The Journal of biological chemistry 2005
Show all 3 references for ABIN390305
Human Polyclonal Kallikrein 5 Primary Antibody for WB - ABIN108461
Egelrud, Brattsand, Kreutzmann, Walden, Vitzithum, Marx, Forssmann, Mägert: hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. in The British journal of dermatology 2005
Human Polyclonal Kallikrein 5 Primary Antibody for ELISA, WB - ABIN188845
Michael, Pampalakis, Mikolajczyk, Malm, Sotiropoulou, Diamandis: Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. in The Journal of biological chemistry 2006
the pruritogenic action of KLK5 may be primarily mediated by PAR2 (show F2RL1 Antibodies) receptors
findings illustrate the crucial role of protease regulation in skin homeostasis and inflammation, and establish KLK5 inhibition as a major therapeutic target for NS
The cloning and characteriazation of recombinant Klk5 is reported.
the expression level of hK5 in tumor stromal cells is a promising biomarker for poor prognosis in TNBC.
This report demonstrates that concurrent loss of KLK5 and KLK7 (show KLK7 Antibodies) associates with a poor clinical outcome in Oral Squamous-Cell Carcinoma and could therefore serve as prognostic marker in this disease.
Low KLK5 expression is associated with breast cancer.
KLK5 is an important contributor to the Netherton syndrome (show SPINK5 Antibodies) proteolytic cascade.
Data indicate that the KLK5 SNP rs268908 was associated with an increased risk of prostate cancer.
Kallikrein 5 and kallikrein 12 (show KLK12 Antibodies) cleave human influenza hemagglutinins and activate thrombolytic zymogens.
KLK5 is required for biochemical processing of profilaggrin (show FLG Antibodies) in human skin.
the inhibition and binding of different SPINK9 (show SPINK9 Antibodies) variants towards KLK5, KLK7 (show KLK7 Antibodies), KLK8 (show KLK8 Antibodies) and KLK14 (show KLK14 Antibodies)
Loss of KLK5 is associated with ovarian cancer.
Increased serum and ascitic fluid KLK5 levels are associated with poor patient outcome, thus underlining the importance of KLK5 as a biomarker for early detection as well as for disease management in ovarian cancer.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its expression is up-regulated by estrogens and progestins. The encoded protein is secreted and may be involved in desquamation in the epidermis. Alternative splicing results in multiple transcript variants encoding the same protein.
Kallikrein 1 renal/pancreas/salivary
, kallikrein 5
, kallikrein-like protein 2
, stratum corneum tryptic enzyme